DURECT (NASDAQ:DRRX) Posts Earnings Results, Hits Expectations

DURECT (NASDAQ:DRRXGet Rating) released its quarterly earnings data on Wednesday. The specialty pharmaceutical company reported ($0.05) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.05), MarketWatch Earnings reports. DURECT had a negative return on equity of 56.80% and a negative net margin of 270.27%. During the same quarter last year, the firm earned ($0.05) earnings per share.

DRRX stock traded down $0.03 on Friday, reaching $0.43. The company’s stock had a trading volume of 772,644 shares, compared to its average volume of 1,032,334. The business has a fifty day simple moving average of $0.55 and a two-hundred day simple moving average of $0.79. DURECT has a 12-month low of $0.40 and a 12-month high of $1.85. The firm has a market cap of $96.90 million, a PE ratio of -2.66 and a beta of 1.47. The company has a debt-to-equity ratio of 0.36, a quick ratio of 7.94 and a current ratio of 8.13.

A number of analysts recently commented on DRRX shares. Zacks Investment Research lowered DURECT from a “hold” rating to a “sell” rating in a research note on Thursday. StockNews.com started coverage on DURECT in a research note on Saturday. They issued a “hold” rating for the company.

In other DURECT news, Director Judith J. Robertson purchased 200,000 shares of the company’s stock in a transaction that occurred on Monday, March 14th. The stock was bought at an average price of $0.59 per share, with a total value of $118,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 5.20% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the business. Janus Henderson Group PLC bought a new position in DURECT in the third quarter worth $29,000. BNP Paribas Arbitrage SA raised its holdings in DURECT by 330.0% in the third quarter. BNP Paribas Arbitrage SA now owns 43,064 shares of the specialty pharmaceutical company’s stock worth $55,000 after purchasing an additional 33,050 shares in the last quarter. Bank of America Corp DE raised its holdings in DURECT by 186.2% in the fourth quarter. Bank of America Corp DE now owns 73,390 shares of the specialty pharmaceutical company’s stock worth $73,000 after purchasing an additional 47,747 shares in the last quarter. Invesco Ltd. raised its holdings in DURECT by 25.7% in the third quarter. Invesco Ltd. now owns 97,886 shares of the specialty pharmaceutical company’s stock worth $125,000 after purchasing an additional 20,009 shares in the last quarter. Finally, Wells Fargo & Company MN raised its holdings in DURECT by 53.6% in the fourth quarter. Wells Fargo & Company MN now owns 143,571 shares of the specialty pharmaceutical company’s stock worth $141,000 after purchasing an additional 50,122 shares in the last quarter. Institutional investors and hedge funds own 50.60% of the company’s stock.

DURECT Company Profile (Get Rating)

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.

Featured Articles

Earnings History for DURECT (NASDAQ:DRRX)

Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.